Roughly half of all U.S. children, about 35 million, receive their health coverage through Medicaid or the Children’s Health Insurance Program. Most of these youngsters come from low-income families, and the programs also serve the vast majority of children who live in foster care. On October 13, a new federal rule will begin to strip those programs of funding for gender-affirming care, a shift that will affect millions of already vulnerable patients.
The rule was drafted by the Centers for Medicare and Medicaid Services (CMS) in December 2025 and implements a six-month “tapering period” after which federal money can no longer be used for puberty blockers, hormone therapy, or other treatments endorsed by the American Academy of Pediatrics. President Donald Trump and his allies have framed the change as a cost-saving measure, yet CMS projects a saving of only $138 million over ten years: about 0.002 % of the program’s total budget.
How the rule reshapes coverage for queer youth
Under the new policy, a child who has been prescribed puberty blockers by a qualified physician will lose Medicaid reimbursement after the taper period ends, even if a court has already affirmed the medical necessity of the treatment. The rule does not forbid providers from delivering transition-related care, but it removes the principal source of payment for families that cannot afford private insurance. As the Center for Children’s Advocacy noted, the measure “places it out of reach for many children and families who rely on these programs for access to medically necessary healthcare.”
Foster care children bear a disproportionate burden
Research published in *Pediatrics* in 2019 found that roughly 30 % of youth in foster care identify as LGBTQ+, compared with 11.2 % of the national population. Transgender children are up to four times more likely to be in foster care, a disparity linked to family rejection and systemic bias. Because Medicaid is often the only health-insurance option available to children in state-run placements, the funding cut threatens to strip them of the only evidence-based care they can obtain.
Financial arguments clash with medical consensus
CMS administrator Mehmet Oz defended the change, asserting that eliminating “sex-rejecting procedures” follows scientific evidence, saves taxpayers money, and shields children from irreversible harm. In reality, the Department of Health and Human Services has offered only limited proof of such harms, and the projected savings are negligible relative to the program’s overall expenditures. Major medical bodies, including the Endocrine Society, describe puberty blockers as reversible and safe when supervised by specialists.
States now face a choice: allocate their own funds to continue covering gender-affirming services, or follow the federal directive and let coverage lapse entirely for Medicaid-eligible youth. Several states already enforce bans on such treatments regardless of funding source, meaning the new rule could accelerate a nationwide retreat from care for transgender children.
Legal settlements between the Department of Justice and hospitals that previously offered gender-affirming services illustrate the administration’s broader strategy. Those hospitals have been compelled to pay large sums to the government and to establish “detransition clinics,” underscoring a systematic effort to curtail the availability of care for queer youth.
While the rule’s language claims it does not prohibit providers from offering care, the practical effect is to shift the decision-making power from doctors and families to a political agenda. Advocates argue that health care decisions should be guided by clinical expertise, not by partisan policy, especially when the stakes involve irreversible developmental outcomes for children.



